CVS Health Corporation (CVS)
NYSE · Woonsocket, Rhode Island, USA · Founded 1963 · CEO David Joyner
Valuation summary
$215.58 fair value versus $80.04 in the market, a difference of +169.3%. Rated Strong Buy.
| Fair value per share | $215.58 |
| Current share price | $80.04 |
| Upside / downside | +169.3% |
| Bear case | $69.12 |
| Bull case | $448.66 |
| Discount rate (WACC) | 9.4% |
| Terminal growth | 2.40% |
| Market capitalisation | $102B |
| EV / Sales | 0.4x |
About CVS Health Corporation
Founded in 1963 as Consumer Value Stores. David Joyner became CEO in October 2024 after a period of severe underperformance. CVS is unusually vertically integrated: it owns retail pharmacies, Caremark (a large pharmacy benefit manager), and Aetna (a major health insurer). The theory is that owning the whole chain lowers costs; the practice has been that problems in any one part drag down the whole.
Investment case
- Vertical integration across pharmacy, benefits management and insurance is genuinely difficult to replicate.
- Around 9,000 retail locations put a pharmacy within reach of most of the US population.
- Valuation is depressed enough that modest operational improvement could re-rate the shares.
Key risks
- Medicare Advantage utilisation ran far above expectations, causing repeated guidance cuts, and management still describes cost trends as elevated.
- Retail pharmacy faces structural pressure from mail order and Amazon.
- Very heavy debt load following the Aetna acquisition constrains flexibility.
Recent developments
- 2026-08-05 · Q2 2026 revenue $106.1bn, up 7.3%; adjusted EPS $2.58 vs $1.81; full-year adjusted EPS guidance raised to $7.90-$8.10 from $7.30-$7.50 source
Revenue by segment
| Health Services (Caremark) | 47% |
| Health Care Benefits (Aetna) | 33% |
| Pharmacy & Consumer Wellness | 20% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $444.7B | $14.5B |
| Year 2 | $474.7B | $16.5B |
| Year 3 | $506.6B | $18.7B |
| Year 4 | $540.7B | $21.1B |
| Year 5 | $577.1B | $23.8B |
What the street says
A turnaround that is now showing results: in August 2026 CVS raised full-year adjusted EPS guidance to $7.90-$8.10, crediting the Aetna margin recovery plan. Management kept a cautious stance for the rest of the year because of elevated cost trends, so the durability of the Medicare Advantage margin recovery remains the key variable.
Comparable companies: CI · HCA · ELV · COR · MCK · MDLN · IQV · GEHC
Open the interactive model, price chart and sensitivity grid →